Guangdong Hybribio Biotech Co Ltd
Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offers STD real time PCR kits; hepatitis B virus real-tim… Read more
Guangdong Hybribio Biotech Co Ltd - Asset Resilience Ratio
Guangdong Hybribio Biotech Co Ltd (300639) has an Asset Resilience Ratio of 5.65% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Guangdong Hybribio Biotech Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Guangdong Hybribio Biotech Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥242.05 Million | 5.65% |
| Total Liquid Assets | CN¥242.05 Million | 5.65% |
Asset Resilience Insights
- Limited Liquidity: Guangdong Hybribio Biotech Co Ltd maintains only 5.65% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Guangdong Hybribio Biotech Co Ltd Industry Peers by Asset Resilience Ratio
Compare Guangdong Hybribio Biotech Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for Guangdong Hybribio Biotech Co Ltd (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Guangdong Hybribio Biotech Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 5.41% | CN¥250.29 Million | CN¥4.62 Billion | +0.05pp |
| 2023-12-31 | 5.36% | CN¥307.05 Million | CN¥5.73 Billion | -0.39pp |
| 2022-12-31 | 5.75% | CN¥387.06 Million | CN¥6.73 Billion | -10.25pp |
| 2021-12-31 | 16.00% | CN¥677.14 Million | CN¥4.23 Billion | -14.10pp |
| 2020-12-31 | 30.10% | CN¥860.00 Million | CN¥2.86 Billion | +29.72pp |
| 2019-12-31 | 0.39% | CN¥5.00 Million | CN¥1.30 Billion | -- |